Has this become a lifestyle company for the CEO and senior management? The new chairman ( appointed by the CEO) seems only interested in retaining the poorly performing management team. Negative return over 5 years, in what should have been the most exciting period ( post FDA approval). Surely it is time for a change. Enough of the lies and false promises.
looking forward to phi/parvismelanotide results Cy 23 as promised
Ann: Chair Elect Letter, page-8
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.16 |
Change
0.090(0.60%) |
Mkt cap ! $759.1M | |||
| Open | High | Low | Value | Volume |
| $15.12 | $15.44 | $15.02 | $1.063M | 70.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 126 | $15.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.27 | 764 | 3 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| CUV (ASX) Chart |